Mahta Ostadian
Psychiatry · Southlake, TXNPI 1003044595
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 31.0% of the total. Reporting peaked in 2021 at $348 and has fallen 83.2% since, to $59 in 2025.
Across 84 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$469
- AbbVie$307
- Bausch Health US, LLC$103
- Lundbeck LLC$103
- Otsuka America Pharmaceutical, Inc.$73
- Sunovion Pharmaceuticals Inc.$70
- plus $386 from 14 others
What the payments were for
- Food & beverage$1,48198%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $469 |
| AbbVie(2 entities) | 18 | $307 |
| Bausch Health US, LLC | 6 | $103 |
| Lundbeck LLC | 5 | $103 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Sunovion Pharmaceuticals Inc. | 5 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Ironshore Pharmaceuticals Inc. | 2 | $45 |
| Medtronic | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Shire North American Group Inc | 2 | $24 |
| Neuronetics, Inc. | 2 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Merck | 1 | $14 |
How this compares
$1,511 in reported general payments places this provider in the 75th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 18 | $365 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $196 |
| Trazodone Hcl | 11 | $61 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Southlake
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.